Jianping Huang

CEO Immunogenik

Seminars

Thursday 19th February 2026
Installing GPS on CAR T Cells: First-in-Human Phase I Trial of 8R-70CAR in Glioblastoma
1:00 pm
  • First-in-human Phase I clinical trial of 8R-70CAR T cells in GBM
  • Novel IL-8 receptor “GPS” design to improve CAR T cell trafficking
  • Early clinical signals of extended survivals
Tuesday 17th February 2026
Exploring Strategies to Define Direct Vs Indirect Target Engagement with Glioblastomas
11:00 am
  • Join this workshop to establish a clear framework for defining direct target engagement direct vs indirect target engagement
  • Navigating the application of cutting-edge preclinical methodologies to confirm on-target binding with GBM cells such as mass spectrometry, thermal shift assays and radiolabels compounds for PET imaging to visualize drugtarget engagement.
  • Analyzing changes in signalling pathways, gene expression and immune cell phenotypes within the GBM tumour microenvironment
  • Advancing biomarker tracking within the blood-brain barrier to track drug effect with ctDNA and immune markers
  • Deepening the understanding of direct vs indirect engagement to understand the design rationale of combination therapies
  • Driving the analysis of PK/PD markers to monitor the emergence of drug resistance in recurring GBMs
Jianping Huang, speaking at the 7th Glioblastoma Drug Development Summit